These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 16431861)

  • 1. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.
    Sáenz Y; Zarazaga M; Briñas L; Ruiz-Larrea F; Torres C
    J Antimicrob Chemother; 2003 Apr; 51(4):1001-5. PubMed ID: 12654733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
    Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
    J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).
    Davies TA; Goldschmidt R; Pfleger S; Loeloff M; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2003 Aug; 52(2):168-75. PubMed ID: 12837740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and epidemiology of levofloxacin resistance in Streptococcus pneumoniae: experience from a tertiary referral hospital in England.
    Orr D; Wilkinson P; Moyce L; Martin S; George R; Pichon B
    J Antimicrob Chemother; 2010 Mar; 65(3):449-52. PubMed ID: 20019170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
    Ip M; Chau SS; Chi F; Qi A; Lai RW
    J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
    Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
    Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R; Paglietti B; Murgia M; Dawar R; Uzzau S; Cappuccinelli P; Deb M; Aggarwal P; Rubino S
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.